HM 12525A

Drug Profile

HM 12525A

Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM12525A; JNJ-64565111; LAPS GLP/GCG; LAPS- GLP/Glucagon; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypoglycaemics; Drug conjugates; Gastrointestinal hormones; Glucagon-like peptides; Immunoconjugates; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 30 Nov 2016 Janssen Research & Development suspends patient recruitment in a phase I trial for Type-2 diabetes mellitus in Germany (SC) (NCT02862431)
  • 01 Jul 2016 Janssen Research & Development initiates a phase I trial for Type-2 diabetes mellitus in Germany (SC) (NCT02862431)
  • 09 Nov 2015 Hanmi Pharmaceutical plans a phase II trial for HM 12525A
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top